stoxline Quote Chart Rank Option Currency Glossary
  
MacroGenics, Inc. (MGNX)
2.56  0.1 (4.07%)    02-14 16:00
Open: 2.49
High: 2.59
Volume: 386,665
  
Pre. Close: 2.46
Low: 2.46
Market Cap: 161(M)
Technical analysis
2025-02-14 4:49:44 PM
Short term     
Mid term     
Targets 6-month :  3.47 1-year :  3.93
Resists First :  2.97 Second :  3.36
Pivot price 2.79
Supports First :  2.33 Second :  1.94
MAs MA(5) :  2.47 MA(20) :  2.86
MA(100) :  3.39 MA(250) :  6.7
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  13.2 D(3) :  7.8
RSI RSI(14): 35.4
52-week High :  21.87 Low :  2.33
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MGNX ] has closed above bottom band by 28.8%. Bollinger Bands are 27.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.59 - 2.6 2.6 - 2.62
Low: 2.44 - 2.45 2.45 - 2.46
Close: 2.54 - 2.56 2.56 - 2.58
Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Headline News

Tue, 11 Feb 2025
Further weakness as MacroGenics (NASDAQ:MGNX) drops 11% this week, taking one-year losses to 86% - Simply Wall St

Fri, 07 Feb 2025
Lost Money on MacroGenics, Inc. (MGNX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - ACCESS Newswire

Fri, 07 Feb 2025
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Thu, 06 Feb 2025
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Sat, 14 Dec 2024
MacroGenics' SWOT analysis: oncology firm faces pipeline challenges, stock outlook mixed - Investing.com

Tue, 05 Nov 2024
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 63 (M)
Shares Float 52 (M)
Held by Insiders 2.6 (%)
Held by Institutions 93.6 (%)
Shares Short 5,280 (K)
Shares Short P.Month 5,400 (K)
Stock Financials
EPS -1.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.9
Profit Margin -69.1 %
Operating Margin 48.9 %
Return on Assets (ttm) -22.2 %
Return on Equity (ttm) -62.2 %
Qtrly Rev. Growth 964.7 %
Gross Profit (p.s.) -0.82
Sales Per Share 2.25
EBITDA (p.s.) -1.59
Qtrly Earnings Growth 220.5 %
Operating Cash Flow -58 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -1.64
PEG Ratio 0
Price to Book value 1.34
Price to Sales 1.13
Price to Cash Flow -2.78
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android